Characteristics and Outcomes of Patients with Early or Late Uveal Melanoma Metastasis: A Review
Ocular Oncology and Pathology · 28.04.2026 · 1-12
DOI: 10.1159/000552152 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Ocular Oncology and Pathology, online erschienen am 28.04.2026. Verfasst von Kevin Lawrence Lin und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Kinghorn Cancer Centre, St. Vincent's Hospital Sydney, Sydney, NSW, Australia. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
Uveal melanoma (UM) metastasis follows variable temporal trajectories, with recurrences ranging from rapid onset to decades post primary therapy. Outcomes after metastasis also vary significantly. Predicting high-risk “early” progressors from “late” recurring phenotypes would facilitate tailored approaches to management.
Methods
A literature review was conducted to synthesise clinicopathologic and molecular predictors of metastatic latency and their impact on survival outcomes in patients with UM.
Results
Early dissemination is associated with older age, male sex, larger basal dimensions, and ciliary body involvement. Genetically, monosomy 3, 8q gain, and BAP1 loss drives a rapid-progression phenotype and poor survival. Conversely, SF3B1 mutations define a distinct late-onset cohort (median: >6 years) with persistent lifetime risk. PRAME expression significantly accelerates metastatic kinetics, even in gene expression profiling class 1 tumours. While early recurrence correlates with dismal outcomes, late-onset disease is associated with extended post-metastasis survival and greater eligibility for interventions like liver-directed therapy.
Conclusion
Metastatic timing is related to biologic rather than stochastic determinants. Integrating molecular profiling with clinical staging and patient factors allows for more precise temporal risk stratification. These insights are essential for tailoring surveillance intensity and selecting candidates for emerging adjuvant therapies, such as tebentafusp and protein kinase C inhibitors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Kinghorn Cancer Centre, St. Vincent's Hospital Sydney, Sydney, NSW, Australia.
- Ocular Oncology Unit, Sydney Eye Hospital, Sydney, NSW, Australia.
- University of Liverpool, Liverpool, UK.
- Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
- Northwell Health Cancer Institute, New Hyde Park, NY, USA.
- Pulse Infoframe Inc., London, ON, Canada.
Zitieren
APA
Lin, K. L., Lim, L. A., Sacco, J. J., Butler, M., Carvajal, R., Gwadry-Sridhar, F., & Joshua, A. (2026). Characteristics and Outcomes of Patients with Early or Late Uveal Melanoma Metastasis: A Review. Ocular Oncology and Pathology, 1-12. https://doi.org/10.1159/000552152
Vancouver
Lin KL, Lim LA, Sacco JJ, Butler M, Carvajal R, Gwadry-Sridhar F, et al. Characteristics and Outcomes of Patients with Early or Late Uveal Melanoma Metastasis: A Review. Ocular Oncology and Pathology. 2026:1-12. doi:10.1159/000552152
BibTeX
@article{Lin2026,
author = {Lin, Kevin Lawrence and Lim, Li-Anne and Sacco, Joseph J and Butler, Marcus and Carvajal, Richard and Gwadry-Sridhar, Femida and Joshua, Anthony},
title = {Characteristics and Outcomes of Patients with Early or Late Uveal Melanoma Metastasis: A Review},
journal = {Ocular Oncology and Pathology},
year = {2026},
pages = {1--12},
doi = {10.1159/000552152}
}
EUVIMED